Table 1.

Randomized phase III trials comparing first-generation epidermal growth factor receptor-tyrosine kinase inhibitors to platinum-based combination chemotherapy as a first-line treatment in patients with epidermal growth factor receptor-mutated non-small cell lung cancer

Ref.	Treatment	Number of patients	Age	Response rate (%)	Median PFS (mo)	Median OS (mo)
WJTOG3405[9]	gefitinib CDDP + TXT	86 86	< 75	62 32	9.2 6.3 HR, 0.48; P < 0.001	35.5 38.8 HR, 1.64; P = 0.211
NEJ002[10]	gefitinib CBDCA + PTX	114 114	< 75	74 31	10.8 5.4 HR, 0.30; P < 0.001	30.5 23.6 HR, 0.89; NS
OPTIMAL[11]	erlotinib CBDCA + GEM	82 72	≥ 18	83 36	13.1 4.6 HR, 0.16; P < 0.001	22.7 28.9 HR, 1.04 NS
EURTAC[12]	erlotinib Platinum + TXT/GEM	86 87	≥ 18	58 15	9.7 5.2 HR, 0.37; P < 0.001	19.3 19.5 HR, 1.04; NS

EGFR: Epidermal growth factor receptor; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; OS: Overall survival; CDDP: Cisplatin; TXT: Docetaxel; PTX: Paclitaxel; GEM: Gemcitabine; CBDCA: Carboplatin; NR: Not reached; HR: Hazard ratio; NS: Not significant.